GRM5 and migraine disorder: The NAM mGlu5 antagonist ADX10059, specifically developed for migraine prevention with a focus on migraine with aura [154], has been shown to attenuate vasodilator responses to meningeal stimulation in a rodent model, in a manner comparable to naratriptan, and to reduce trigeminocervical neuronal firing in response to dural stimulation, thereby demonstrating both peripheral and central anti-migraine effects.